VBI Vaccines (VBIV) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
VBI Vaccines Inc. has updated stakeholders on its restructuring process, including a granted provisional relief under Chapter 15 and a scheduled court hearing, alongside the news that its shares will be delisted from Nasdaq effective August 8, 2024, without plans to appeal. The company is under legal advisement from several firms and Ernst & Young Inc. has been appointed as Monitor in the CCAA proceedings.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.